Theravance Biopharma, a Cayman Islands-based organ-selective medicine focused biopharmaceutical company,  announced positive results from the second Phase-3 study of its hypertension drug. The study, titled 0170, assessing the durability of clinical effect of ampreloxetine compared to placebo for the treatment of symptomatic nOH, demonstrated significant benefit in patients with multiple system atrophy (MSA),  compared to placebo.  The company said that the study 0170 was a 22-week Phase 3 study consisting of a 16-week open-label period followed by a 6-week double-blind, placebo-controlled, randomised withdrawal period. It showed benefits to MSA patients in multiple endpoints with no indication of worsening of supine hypertension based on 24-hour monitoring.